Amneal Pharmaceuticals, Inc , together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.
infoAmneal Pharmaceuticals is a small cap stock with a total market cap of 1.25B.
infoThey trade on the NYSE and had their IPO 5 years and 3 months ago.
infoAmneal Pharmaceuticals currently employs 7600 people.
infoAs of Wednesday, Aug 23 2023, Amneal Pharmaceuticals’s share price is $4.09.
News Relating to Amneal Pharmaceuticals
PennyStocks
Penny Stocks To Buy? 5 To Watch With Big News This Week
Monday Aug 07 2023 at 14:08
Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation and thereby increasing market volatility.
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
Friday Aug 04 2023 at 09:02
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.19 per share a year ago.
Zacks Investment Research
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Friday Jul 21 2023 at 13:42
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Motley Fool
Why Shares of Amneal Pharmaceuticals Are Plunging Wednesday
Wednesday Jul 05 2023 at 13:23
Amneal has more than 270 products. On Tuesday, the company launched a generic for Xyrem to treat excessive daytime sleepiness.
Zacks Investment Research
Amneal (AMRX) Shares Down on CRL for Parkinson’s Disease Drug
Wednesday Jul 05 2023 at 10:47
Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson’s disease.
Reuters
US FDA declines to approve Amneal Pharma’s Parkinson’s drug
Monday Jul 03 2023 at 14:38
The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals’ drug for Parkinson’s disease due to inadequate safety data on the treatment to help control symptoms in patients for a longer duration, the company said on Monday.
PennyStocks
Best Penny Stocks To Buy Now? 4 to Watch Under $5 This Week
Thursday May 18 2023 at 12:07
Penny stocks to watch under $5. The post Best Penny Stocks To Buy Now?
PennyStocks
3 Top Penny Stocks To Watch After Big News This Week
Tuesday May 16 2023 at 13:59
Hot penny stocks with big news this week. The post 3 Top Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Market Watch
Amneal Pharmaceuticals’ stock soars 14% premarket after company offers upbeat Q1 guidance
Monday Apr 17 2023 at 06:53
Amneal Pharmaceuticals Inc.’s stock AMRX, -2.16% soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter guidance that topped consensus estimates. Bridgewater, N.J.
CNBC Television
Generic drugs are most likely to face shortages due to market failures in affordability
Wednesday Mar 29 2023 at 17:26
CNBC’s Meg Tirrell joins ‘Closing Bell Overtime’ to discuss growing pharmaceutical shortages, increasing debt hindering generic drug availability, and more.
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
Thursday Mar 02 2023 at 09:02
Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PennyStocks
Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week
Monday Feb 13 2023 at 14:47
Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?
Investors Business Daily
Intercept Surges To Four-Month High After Staving Off Amneal’s Generic For 11 Years
Wednesday Jan 25 2023 at 13:15
Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
Business Wire
Amneal to Participate at Upcoming Investor Conferences
Wednesday Nov 23 2022 at 08:00
BRIDGEWATER, N.J.–( BUSINESS WIRE )–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences:
Zacks Investment Research
FDA Accepts Amneal’s (AMRX) Parkinson’s Candidate NDA For Review
Monday Nov 14 2022 at 15:48
Amneal Pharmaceuticals’ (AMRX) shares rise after the company announces that its Parkinson’s candidate IPX203 NDA has been accepted for review by the FDA.
Seeking Alpha
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2022 Earnings Call Transcript
Friday Nov 04 2022 at 13:16
Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q3 2022 Earnings Conference Call November 4, 2022 8:30 AM ET Company Participants Chirag Patel – Co-Founder, Co-Chief Executive Officer Chintu Patel – Co-Founder and Co-Chief Executive Officer Anastasios Konidaris – Executive Vice President and Chief Financial Officer Harsher Singh – Senior Vice President, Biosciences Jason Daly – Senior Vice President and Chief Legal Officer Gustavo Pesquin – EVP, Specialty Conference Call Participants David Amsellem – Piper Sandler Michaela Diverio – Barclays Gary Nachman – BMO Capital Markets Nathan Rich – Goldman Sachs Elliot Wilbur – Raymond James Gregory Fraser – Truist Securities Operator Hello everyone and welcome to the Amneal Third Quarter 2022 Conference Call. My name is Emily and I will be your operator today.
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates
Friday Nov 04 2022 at 09:02
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q2 2022 Results – Earnings Call Transcript
Friday Aug 05 2022 at 15:46
Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Anthony DiMeo – Senior Director of Investor Relations Chirag Patel – Co-Founder, Co-Chief Executive Officer, President & Director Chintu Patel – Co-Founder & Co-Chief Executive Officer Anastasios Konidaris – Executive Vice President & Chief Financial Officer Harsher Singh – Head of Biosciences Jason Daly – Senior Vice President, Chief Legal Officer & Corporate Secretary Conference Call Participants Balaji Prasad – Barclays Nathan Rich – Goldman Sachs David Amsellem – Piper Sandler Gary Nachman – BMO Capital Markets Greg Fraser – Truist Securities Elliot Wilbur – Raymond James Ekaterina Knyazkova – JPMorgan Operator Hello and welcome to today’s Amneal 2Q 2022 Earnings Conference Call. My name is Elliot and I will be coordinating your call today.
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates
Friday Aug 05 2022 at 09:02
Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Amneal to Report Second Quarter 2022 Results on August 5, 2022
Friday Jul 08 2022 at 08:00
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022. The financial results and live webcast will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com
Seeking Alpha
Amneal Pharmaceuticals, Inc. (AMRX) Management Team on Q1 2022 Results – Earnings Call Transcript
Wednesday May 04 2022 at 14:04
Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Tony DiMeo – Head-Investor Relations Chirag Patel – President and Co-Chief Executive Officer Chintu Patel – Co-Chief Executive Officer Tasos Konidaris – Chief Financial Officer Andy Boyer – Executive Vice President and Chief Commercial Officer-Generics Conference Call Participants Mikaela Franceschina – Barclays David Amsellem – Piper Sandler Gary Nachman – BMO Capital Markets Operator Hello and welcome to Amneal’s First Quarter 2022 Conference Call. My name is Alex and I will be coordinating the call today.
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates
Wednesday May 04 2022 at 09:02
Amneal (AMRX) delivered earnings and revenue surprises of 0% and 0.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old Management
Wednesday Mar 30 2022 at 15:26
Amneal Pharmaceuticals shares have fallen in value from $24 to $4 since September 2018.
Seeking Alpha
Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results – Earnings Call Transcript
Wednesday Mar 02 2022 at 13:13
Amneal Pharmaceuticals (AMRX) CEO, Chirag Patel on Q4 2021 Results – Earnings Call Transcript
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Lags Q4 Earnings Estimates
Wednesday Mar 02 2022 at 09:10
Amneal (AMRX) delivered earnings and revenue surprises of -5.26% and 1.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Wednesday Feb 23 2022 at 16:09
Amneal (AMRX) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Friday Feb 04 2022 at 10:43
Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.
Business Wire
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
Friday Feb 04 2022 at 08:00
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2022. The financial results and live webcast will be accessible through the Investor Relations section of the Company’s website
Zacks Investment Research
Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?
Friday Jan 28 2022 at 10:46
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor’s perspective right now? Read on to know more.
Benzinga
Amneal’s $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity
Wednesday Jan 05 2022 at 07:35
Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol’s Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $83.5 million in cash. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market.
Amneal Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Amneal Pharmaceuticals’s Altman Z-score is 1.25 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Amneal Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $120.92K of common stock in Amneal Pharmaceuticals on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Amneal Pharmaceuticals’s Income Quality of 26.75 is greater than its Industry Group of 0.69 (3776.8% greater)
Amneal Pharmaceuticals’s Income Quality of 26.75 is greater than its Major Industry Group of 0.71 (3667.6% greater)
Amneal Pharmaceuticals’s Income Quality of 26.75 is greater than its Sector of 0.75 (3466.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Amneal Pharmaceuticals’s Current Ratio of 1.83 is lower than its Industry Group of 4.76 (-61.6% lower)
Amneal Pharmaceuticals’s Current Ratio of 1.83 is lower than its Major Industry Group of 4.32 (-57.6% lower)
Amneal Pharmaceuticals’s Current Ratio of 1.83 is lower than its Sector of 2.6 (-29.6% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (110.47 & -1.27)
Cannot compare a negative PE Ratio (110.47 & -1.1)
Cannot compare a negative PE Ratio (110.47 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Amneal Pharmaceuticals’s PB Ratio of 8.31 is greater than its Industry Group of 1.34 (520.1% greater)
Amneal Pharmaceuticals’s PB Ratio of 8.31 is greater than its Major Industry Group of 1.4 (493.6% greater)
Amneal Pharmaceuticals’s PB Ratio of 8.31 is greater than its Sector of 1.62 (413.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Amneal Pharmaceuticals’s ROE of 0.08 is greater than its Industry Group of -0.44 (118.2% greater)
Amneal Pharmaceuticals’s ROE of 0.08 is greater than its Major Industry Group of -0.38 (121.1% greater)
Amneal Pharmaceuticals’s ROE of 0.08 is greater than its Sector of -0.03 (366.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Amneal Pharmaceuticals’s ROCE of 0.08 is greater than its Industry Group of -0.42 (119.0% greater)
Amneal Pharmaceuticals’s ROCE of 0.08 is greater than its Major Industry Group of -0.37 (121.6% greater)
Amneal Pharmaceuticals’s ROCE of 0.08 is greater than its Sector of -0.04 (300.0% greater)
Derived from SEC.GOV filing dataopen_in_new